Our Published Research: The BG01-4™ Clinical Trial

  • Study design: Phase 1/2A double-blind, randomised, placebo-controlled trial
  • Duration: 4 weeks
  • Trial registration: Registered prospectively (25 October 2021) with the Australian New Zealand Clinical Trials Registry, ACTRN12621001441808p
  • Ethics approval: Bellberry Human Research Ethics Committee, Australia (2021-09-1137)

Citation

Patch, C.; Pearce, A.J.; Cheng, M.; Boyapati, R.; Brenna, J.T. Bacillus Subtilis (BG01-4™) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial. Nutrients 2023, 15, 4490. https://doi.org/10.3390/nu15214490

Download the paper (PDF)

Back to blog